2018
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
ABLA, Oussama; Eric JACOBSEN; Jennifer PICARSIC; Zdenka KŘENOVÁ; Ronald JAFFE et al.Základní údaje
Originální název
Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
Autoři
ABLA, Oussama; Eric JACOBSEN; Jennifer PICARSIC; Zdenka KŘENOVÁ; Ronald JAFFE; Jean-Francois EMILE; Benjamin H. DURHAM; Jorge BRAIER; Frederic CHARLOTTE; Jean DONADIEU; Fleur COHEN-AUBART; Carlos RODRIGUEZ-GALINDO; Carl ALLEN; James A. WHITLOCK; Sheila WEITZMAN; Kenneth L. MCCLAIN; Julien HAROCHE a Eli L. DIAMOND
Vydání
Blood, Washington, American Society of Hematology, 2018, 0006-4971
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30205 Hematology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 16.601
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/18:00104163
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
Rosai-Dorfman-Destombes disease
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 9. 2. 2019 21:56, Soňa Böhmová
Anotace
V originále
Rosai-Dorfman-Destombes disease (RDD) is a rare non-Langerhans cell histiocytosis characterized by accumulation of activated histiocytes within affected tissues. RDD, which now belongs to the R group of the 2016 revised histiocytosis classification, is a widely heterogeneous entity with a range of clinical phenotypes occurring in isolation or in association with autoimmune or malignant diseases. Recent studies have found NRAS, KRAS, MAP2K1, and ARAF mutations in lesional tissues, raising the possibility of a clonal origin in some forms of RDD. More than 1000 reports have been published in the English literature; however, there is a lack of consensus regarding approach for the clinical management of RDD. Although in most cases RDD can be observed or treated with local therapies, some patients with refractory or multifocal disease experience morbidity and mortality. Here we provide the first consensus multidisciplinary recommendations for the diagnosis and management of RDD. These recommendations were discussed at the 32nd Histiocyte Society Meeting by an international group of academic clinicians and pathologists with expertise in RDD. We include guidelines for clinical, laboratory, pathologic, and radiographic evaluation of patients with RDD together with treatment recommendations based on clinical experience and review of the literature.